A variant in the 17B-hydroxysteroid dehydrogenase 13 (HSD17B13) gene has been reported to protect against NAFLD, progression from hepatic steatosis to steatohepatitis (NASH), alcoholic liver disease (ALD), and associated liver fibrosis/cirrhosis [7]. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.